கட்டி மாதிரிகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from கட்டி மாதிரிகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In கட்டி மாதிரிகள் Today - Breaking & Trending Today

Bicycle Therapeutics Announces Presentations at the AACR Annual Meeting 2021

Bicycle Therapeutics Announces Presentations at the AACR Annual Meeting 2021
-
BT7480 to be presented in a “New Drugs on the Horizon” session; on-track to enter the clinic in 2H’21
CAMBRIDGE, England & BOSTON (BUSINESS WIRE) Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (
Bicycle®) technology, today announced that for the first time, preclinical work describing the discovery of BT7480, a novel Nectin-4/CD137 tumor-targeted immune cell agonist (TICA
TM), will be presented virtually in a “New Drugs on the Horizon” session at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 10-15, 2021. Additional work covering TICAs and ....

United Kingdom , United States , Matthew Deyoung , Heather Savelle , Exchange Commission , American Association For Cancer Research , Pediatric Preclinical Testing Consortium , Bicycle Therapeutics , American Association , Cancer Research , Annual Meeting , Bicycle Toxin Conjugates , Nicholas Keen , Chief Scientific Officer , Biomarkers Predictive , Therapeutic Benefit , Immunomodulatory Agents , Molecular Classification , Therapeutic Outcomes , Rapid Accumulation , Cytotoxic Payload , Tumor Tissue Drives , Tumor Models , Novel Drug Delivery Systems , New Drugs , Late Breaking Mini Symposium ,

Bicycle Therapeutics plc: Bicycle Therapeutics Announces Presentations at the AACR Annual Meeting 2021

Bicycle Therapeutics plc: Bicycle Therapeutics Announces Presentations at the AACR Annual Meeting 2021
-
BT7480 to be presented in a New Drugs on the Horizon session; on-track to enter the clinic in 2H 21
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (
Bicycle) technology, today announced that for the first time, preclinical work describing the discovery of BT7480, a novel Nectin-4/CD137 tumor-targeted immune cell agonist (TICA
TM), will be presented virtually in a New Drugs on the Horizon session at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 10-15, 2021. Additional work covering TICAs and ....

United States , United Kingdom , Matthew Deyoung , Heather Savelle , Exchange Commission , American Association For Cancer Research , Pediatric Preclinical Testing Consortium , American Association , Cancer Research , Annual Meeting , Bicycle Toxin Conjugates , Nicholas Keen , Chief Scientific Officer , Biomarkers Predictive , Therapeutic Benefit , Immunomodulatory Agents , Molecular Classification , Therapeutic Outcomes , Rapid Accumulation , Cytotoxic Payload , Tumor Tissue Drives , Tumor Models , Novel Drug Delivery Systems , New Drugs , Late Breaking Mini Symposium , Bicycle Toxin Conjugate ,

NYUAD researchers develop high throughput paper-based arrays of 3D tumor models

Credit: NYU Abu Dhabi
Abu Dhabi, UAE, February 22: By engineering common filter papers, similar to coffee filters, a team of NYU Abu Dhabi researchers have created high throughput arrays of miniaturized 3D tumor models to replicate key aspects of tumor physiology, which are absent in traditional drug testing platforms. With the new paper-based technology, the formed tumor models can be safely cryopreserved and stored for prolonged periods for on-demand drug testing use. These cryopreservable tumor models could provide the pharmaceutical industry with an easy and low cost method for investigating the outcomes of drug efficacy, potentially bolstering personalized medicine. The developed technology can be transferred to other trending therapeutic applications such as measuring tumor response to drug concentration gradients, studying cancer cell signaling pathways, and investigations of invasive tumors. ....

United States , Abu Dhabi , Mohammada Qasaimeh , Principal Investigator Of The Laboratory , Cryopreservable Arrays , Tumor Models , High Throughput Drug Screening , Assistant Professor , Biomedical Engineering , Principal Investigator , Bisan Samara , Paper Based Cell Cryopreservation , Advanced Biosystems , Biomedical Environmental Chemical Engineering , Medicine Health , Pharmaceutical Science , Research Development , ஒன்றுபட்டது மாநிலங்களில் , ப்ரிந்ஸிபல் புலனாய்வாளர் ஆஃப் தி ஆய்வகம் , கட்டி மாதிரிகள் , உதவியாளர் ப்ரொஃபெஸர் , உயிர் மருத்துவ பொறியியல் , ப்ரிந்ஸிபல் புலனாய்வாளர் , பிசன் சமாரா , உயிரி தொழில்நுட்பவியல் , உயிர் மருத்துவ சுற்றுச்சூழல் இரசாயன பொறியியல் ,